Abstract
Introduction
Pulmonary arterial hypertension (PAH) is a rare, progressive disease associated with significant morbidity and mortality. The phase 3 STELLAR trial tested sotatercept plus background therapy (BGT) versus placebo plus BGT. BGT was comprised of mono-, double-, or triple-PAH targeted therapy. Building on STELLAR findings, we employed a population health model to assess the potential long-term clinical impact of sotatercept.
Methods
Based on the well-established ESC/ERS 4-strata risk assessment approach, we developed a six-state Markov-type model (low risk, intermediate-low risk, intermediate-high risk, high risk, lung/heart-lung transplant, and death) to compare the clinical outcomes of sotatercept plus BGT versus BGT alone over a lifetime horizon. State-transition probabilities were obtained from STELLAR. Risk stratum-adjusted mortality and lung/heart-lung transplant probabilities were based on COMPERA PAH registry data, and the post-transplant mortality probability was obtained from existing literature. Model outcomes were discounted at 3% annually. Sensitivity analyses were conducted to examine model robustness.
Results
In the base case, sotatercept plus BGT was associated with longer life expectancy from model baseline (16.5 vs 5.1 years) versus BGT alone, leading to 11.5 years gained per patient. Compared with BGT alone, sotatercept plus BGT was further associated with a gain in infused prostacyclin-free life years per patient, along with 683 PAH hospitalizations and 4 lung/heart-lung transplant avoided per 1000 patients.
Conclusions
According to this model, adding sotatercept to BGT increased life expectancy by roughly threefold among patients with PAH while reducing utilization of infused prostacyclin, PAH hospitalizations, and lung/heart-lung transplants. Real-world data are needed to confirm these findings.
Trial Registration
ClinicalTrials.gov identifier, NCT04576988 (STELLAR).
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Why carry out this study? |
Pulmonary arterial hypertension (PAH) is a debilitating condition marked by its progressive nature with a significant burden on morbidity and mortality. |
The phase 3 STELLAR trial has demonstrated the strong clinical benefit of sotatercept as an add-on treatment to stable background therapy for PAH compared to background therapy alone. |
To enhance clinicians’ understanding of the potential long-term treatment effectiveness, we developed a population health model based on STELLAR data to predict the long-term morbidity and mortality outcomes of sotatercept plus background therapy vs background therapy alone for patients with PAH. |
What was learned from this study? |
This study’s findings reveal that adding sotatercept to stable background therapy has the potential to increase life expectancy by roughly threefold among patients with PAH, while reducing utilization of infused prostacyclin, PAH hospitalizations, and lung/heart-lung transplants. |
Introduction
Pulmonary arterial hypertension (PAH) is a rare and progressive disease affecting an estimated 40,000 people in the US and 50,000 across Europe [1,2,3]. Patients living with PAH face considerable morbidity and mortality and experience poor prognoses as a result of increased pulmonary resistance, which leads to right ventricular failure and eventually death [4, 5]. Current median survival is 5–7 years after diagnosis [6,7,8].
Current treatment options for PAH include vasodilators tackling three distinct pathways (prostacyclin, nitric oxide, endothelin) [9]. Sotatercept, an activin signaling inhibitor, can address imbalances in activin/growth differentiation factors and the bone morphogenetic protein signaling. This novel activin receptor type IIA-Fc fusion protein traps activin 2a to improve cardiopulmonary function in patients with PAH and has demonstrated reverse pulmonary arterial wall and right ventricular remodeling [10, 11]. The phase 3 randomized controlled trial STELLAR (NCT04576988) demonstrated the clinical benefit of sotatercept as an add-on treatment to stable background therapy for PAH by showing an increase in the 6-min walking distance (6MWD) result by 40.8 m and time to clinical worsening reduced by 84% (hazard ratio [HR] 0.16, 95% CI 0.08–0.35). Background therapy was defined as the standard of care therapy for PAH at the time of conduct of STELLAR, including mono, double, or triple therapy of some combination of endothelin receptor antagonist (ERA), phosphodiesterase type-5 (PDE-5) inhibitor, soluble guanylate cyclase (sGC) stimulator, prostaglandin I2 (PGI2) analog, and PGI2 agonist [12].
The management of PAH involves lifelong therapeutic intervention, yet clinical evidence for pharmacotherapies in PAH is generally derived from clinical trials of short duration. In this context, assessments based on population health models can serve as a tool in aiding clinical decision-making [13]. By simulating patient disease progression over time, these models can facilitate the extrapolation of short-term trial data over longer periods.
Therefore, we developed a population health model aiming to evaluate the long-term health outcomes of sotatercept plus background therapy versus background therapy alone for the treatment of patients with PAH.
Methods
Overview
We analyzed STELLAR, a phase 3 study of sotatercept, to derive patients’ distribution and transition probabilities across risk strata at baseline and weeks 3, 12, and 24. Subsequently, data were derived from the COMPERA registry to understand behavior of patients with the respectively derived risk profile over time in a real-world cohort and to assess mortality and transplant [8]. A population health model was developed to simulate the disease course of PAH and compare long-term health outcomes associated with sotatercept plus background therapy vs background therapy alone in adult patients with symptomatic PAH (World Health Organization [WHO] functional class [FC] II or III), in line with the definition of the intent-to-treat (ITT) population and treatment arms of STELLAR (sotatercept plus background therapy vs background therapy alone).
The model adopted a lifetime horizon, assumed to be 30 years based on simulation results. These results revealed that a majority of patients, with a baseline mean age of 47.6 years, experienced mortality within this time frame across both arms. The model employed cycle lengths of 3 weeks (first cycle), 9 weeks (second cycle), and 12 weeks (third and subsequent cycles), in line with the visit schedule in STELLAR. Model outcomes were discounted at 3% annually beyond the first model cycle [14].
This study relied on previously conducted studies and did not involve any new studies requiring direct human subject participation; thus, ethics board approval was not required.
Model Structure
A Markov-type model was developed to simulate the disease course of PAH, comprising six mutually exclusive health states: low risk, intermediate-low risk, intermediate-high risk, high risk, lung/heart-lung transplant, and death (Fig. 1). These states were defined in line with the refined four-strata risk assessment, which has been validated across multiple PAH registries and is recommended in the 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) treatment guideline for PAH because of its established prognostic relevance for survival [15]. Specifically, patients are categorized into one of the four risk strata, with those in the higher-risk group having a heightened risk of mortality, PAH hospitalization, and lung transplant [15].
At baseline, all patients enter the model via one of the four risk strata health states (Table 1 and Table 2). The cohort of patients was then followed through the model and could remain in their current health state, transition between the four risk strata health states, or progress to lung/heart-lung transplant or death during each model cycle, according to a set of transition probabilities obtained from STELLAR (Table 1). Across each model cycle, the proportion of patients occupying each health state accrued associated life-years (LYs) over time.
Model Parameters
Population Characteristics
The baseline patient characteristics of the modeled population are shown in Table 2. Additional patient characteristics that were not directly used as model inputs but used for validation purposes are shown in Supplementary Table 2.
Risk-strata Transition Probabilities
STELLAR data were used to calculate transition probabilities across risk strata (either worsening, improvement, or maintenance). Short-term transition probabilities used in the model (i.e., model baseline to week 3, week 3–12, and week 12–24) were based on observed patient transition counts across weeks 0, 3, 12, and 24 in STELLAR. Long-term transition probabilities (i.e., post week 24) were based on observed transition counts from weeks 12–24 in STELLAR, assuming that the short-term outcomes were generalizable to long-term outcomes.
Mortality, by Risk Stratum
Patients with PAH face an increased risk of mortality, with increasingly higher risk as the disease progresses, i.e., vascular remodeling advances [16, 17]. Therefore, to inform long-term all-cause mortality probabilities by risk stratum, parametric regression models were fitted to long-term 5-year survival curves from the COMPERA registry and the French PAH registry (Supplementary Figure 1–3), one of the largest and most representative, prospective multicenter registries in PAH.
In the base case, it was assumed that the addition of sotatercept to background therapy would have an effect on mortality. Specifically, the direct treatment effect observed in the overall STELLAR population (HR for all-cause mortality = 0.25; 95% CI 0.05–1.19 per Merck & Co., Inc., Rahway, NJ, USA, data on file 2023, including a mixed population with any of the four risk strata) was applied to the four risk health states but not the lung/heart-lung transplant state. This assumption was based on the clinical understanding that after transplantation patients would be free of PAH and then discontinue PAH therapy [18, 19].
In summary, any difference in predicted LYs between treatment arms would be driven (1) indirectly by any difference in the estimated proportion of patients staying in each non-death health state and (2) directly by the observed treatment effect in STELLAR. The robustness of observed treatment effect was examined in sensitivity analyses.
Lung/Heart-lung Transplant by Risk Stratum and Post-transplant Mortality
Patients who have reached maximal PAH pharmacotherapy may receive a lung/heart-lung transplant as an end-stage therapeutic option [15]. As per current treatment standards, such as the 2022 ESC/ERS guidelines, we assumed that only patients with intermediate-high or high risk would be eligible for lung/heart-lung transplant (Table 2) [15]. Patients transitioning to the lung/heart-lung transplant health state would remain in this state until death. COMPERA informed lung/heart-lung transplant probabilities. Post-transplant mortality was derived from the literature [20].
PAH Hospitalization by Risk Stratum
Patients with PAH often require hospitalization. We modeled PAH hospitalizations by applying risk stratum-adjusted probabilities of PAH hospitalization to each health state, with higher-risk patients at greater risk of hospitalization. These probabilities were based on observed data from the COMPERA registry (Table 2).
Infused Prostacyclin Escalation and De-escalation by Risk Stratum
Patients with PAH may experience escalation or de-escalation in PAH therapy over the course of the disease [15]. The addition of infused prostacyclin is recommended for patients with intermediate-high or high risk [15].
To reflect treatment change as the disease progresses or improves, we applied risk stratum-specific use of infused prostacyclin to each health state (Table 2). We also assumed that changes in PAH therapy would occur 1 year from model baseline, with alternative time cut-offs explored in sensitivity analyses. In the base case, it was assumed that sotatercept would have a direct and indirect effect on reducing escalation to infused prostacyclin analog use. Specifically, any predicted long-term difference in infused prostacyclin use between treatment arms would be driven (1) indirectly by any difference in the estimated proportion of patients staying in each risk strata health state and (2) directly by the observed treatment effect in STELLAR (risk ratio = 0.33; 95% CI 0.15–0.71 per Merck & Co., Inc., Rahway, NJ, USA, data on file 2023). The uncertainty of observed treatment effect was examined in sensitivity analyses. This analysis technique was utilized in order to increase the robustness of a model.
Model Outcomes
Primary outcomes included: (1) per patient total LYs, (2) per patient infused prostacyclin–free LYs, and (3) the number of PAH hospitalizations and lung/heart-lung transplants per 1000 patients.
Sensitivity Analyses
Deterministic sensitivity analyses (DSAs) and probabilistic sensitivity analyses (PSAs) were conducted to test the uncertainty of the deterministic base case results. DSAs were conducted by varying one parameter at a time. PSA were conducted by simultaneously drawing values for each parameter based on its point estimate and variance information (Table 2). The PSAs were run 1000 times to increase stability of results.
Results
Base Case
Over a 30-year lifetime horizon, the presented model predicted a total of 16.5 years of life in patients receiving sotatercept plus background therapy compared with 5.1 years of life for patients receiving background therapy alone, yielding an additional 11.5 years of life expectancy per patient (Table 3 and Fig. 2).
The infused prostacyclin-free LYs (i.e., years of life during which patients did not have to receive infused prostacyclin) was 14.7 vs 3.1 for sotatercept plus background therapy vs background therapy alone, leading to 11.6 infused prostacyclin-free LYs gained with sotatercept (Table 3).
Sotatercept plus background therapy was also associated with a reduction of 683 PAH hospitalizations and 4 lung/heart-lung transplants per 1000 patients compared with background therapy alone (Table 3).
Sensitivity Analyses
The DSA demonstrated that variations in (1) the time horizon, (2) direct treatment effect of sotatercept on reducing mortality and (3) annual discounting beyond the first model year were the only model parameters with a meaningful impact on model outcomes. Other variations in model inputs had limited impact. Specifically, sotatercept was estimated to confer greater health benefits over a longer time horizon (e.g., 30 years compared to 5 years), while the inclusion of the direct treatment effect of sotatercept on mortality reduction resulted in substantially more favorable outcomes for sotatercept compared with the base case (Table 4).
Additionally, the PSA results were consistent with those of the deterministic base case analysis, indicating its stability (Table 3).
Discussion
Our analysis suggests that adding sotatercept to background therapy is expected to increase life expectancy by approximately 12 years among patients with PAH, while reducing utilization of infused prostacyclin, PAH hospitalizations, and lung/heart-lung transplants compared to background therapy alone.
Sensitivity analyses showed that the results of the base case analysis were robust. In the DSA in which time horizon, the direct treatment effect of sotatercept on reducing mortality, and annual discounting beyond the first model year were varied, sotatercept plus background therapy was consistently associated with fewer all-cause deaths, infused prostacyclin-free life years, PAH hospitalizations, and lung/heart-lung transplants compared with background therapy alone. The PSA results showed the stability of overall results.
The longer life expectancy in sotatercept-treated patients was primarily driven by patients remaining in the low-risk health state for a longer duration.
This analysis has limitations that should be considered when interpreting the results. First, like most population health models, this study relied on trial data to predict patients’ transitions across risk strata health states over a lifetime horizon. As with most PAH trials, STELLAR’s short follow-up period may limit the generalizability of the risk strata transition probabilities beyond the trial period [16, 21]. Additionally, due to the limited number of observed clinical events (e.g., mortality) in STELLAR at the time of our study, long-term real-world data from COMPERA informed additional clinical inputs in our model. We also performed sensitivity analyses to examine to which extent alternative input values would affect the model results. These assessments generally suggest that these limitations may have limited impact, if any, on the model results. Therefore, the model was confirmed in its robustness. Second, our model relied heavily on STELLAR data to inform clinical inputs. Given this, the model’s predictions may be more informative for PAH populations with patient characteristics similar to those of the STELLAR trial population but may not be fully representative of all the patients with PAH, depending on factors such as geographic region, disease severity, and age at diagnosis. This limitation is common for most of the clinical population health models, especially in the context of rare diseases where increasing the study sample size to enhance generalizability presents even greater challenges. However, given that the STELLAR trial demonstrated consistent relative treatment effect of sotatercept across most prespecified subgroups [12], potential differences in patient profiles may have limited impact on the model results. Third, our model does not directly capture the impact of hospitalization on mortality, partly because of the small number of mortality events before and after hospitalization observed in STELLAR. However, given that both hospitalization and mortality rates were linked to risk strata health state occupancy, predicted survival would exhibit consistency with predicted hospitalization, resulting in clinically coherent outcomes within the model. Notably, this limitation could also lead to underestimation of the survival benefit of sotatercept, which might be explored in future modeling studies. More specifically, given that (1) sotatercept was observed to reduce the probability of PAH hospitalization in STELLAR and (2) patients who had PAH hospitalizations would have a higher mortality risk [22,23,24], using the observed treatment effect on reducing mortality (as currently used in our model) might not fully capture all the long-term survival benefit of sotatercept. Finally, while this study aimed at a comprehensive assessment of sotatercept’s health impact, it did not account for the broader impact on patients, caregivers, or society. Examples of outcomes not included in this study include changes in health-related quality of life for patients and caregivers, costs associated with the add-on therapy to patients and society, productivity changes for patients and caregivers, and real-world treatment patterns. Future research may be warranted to assess these broader implications related to sotatercept and other emerging novel therapies, especially within the context of PAH with a substantial disease burden.
Our de novo model design exhibits notable strengths making it a highly informative tool for clinical decision-making. First, our model relies on multiple data sources, starting from STELLAR, which is distinguished from other PAH trials in its unique characterization of maximized background therapy, as well as the long-term real-world data obtained from COMPERA, one of the largest and most representative prospective multicenter PAH registries. The utilization of this extensive data set increases the external validity of our results. Second, our model relies on the most recent risk strata classification approach for assessing PAH severity and progression and thus is expected to provide more valid estimates compared to most prior models that relied on the traditional WHO FC classification to predict long-term outcomes [18, 19, 25]. More specifically, the WHO FC categories, ranging from FC I (most mild) to FC IV (most severe), have historically been widely used by clinicians to classify PAH severity, predict survival, and measure treatment effectiveness [26]. However, this clinician-rated classification approach presents certain limitations. In particular, it relies exclusively on clinicians’ judgment of patient-reported symptoms, without accounting for objective measures of PAH severity, which can lead to potential interrater variation [16, 27,28,29]. Additionally, WHO FC employs a single variable to measure disease severity, which may not fully capture patients’ prognosis [28]. As clinical assessment is essential for disease management, there was a pressing need for a more effective and objective assessment tool to provide key insights for establishing PAH prognosis and severity [16]. To address this, the 2022 ESC/ERS guidelines introduced an alternative comprehensive risk assessment strategy for the diagnosis and treatment of PH [15]. Using cut-off values, this multivariable risk assessment evaluates PAH-related prognostic indicators such as WHO FC, 6MWD results, and N-terminal pro-brain natriuretic peptide plasma levels to classify patients into four risk strata: low, intermediate-low, intermediate-high, and high risk. In contrast to the WHO FC, this risk stratification approach emphasizes a comprehensive evaluation of multiple prognostic markers, thereby offering more objective diagnostic and prognostic information. This stratification approach has demonstrated greater sensitivity to prognostic changes in risk, as well as improved differentiation of long-term survival, as validated in multiple PAH registries [17, 30,31,32,33].
Moreover, our study’s LY estimates were aligned with those generated in previously published population health models evaluating PAH treatments (Supplementary Table 3) [18, 19, 25]. Notably, these comparisons are only informative to some extent given that our model relied on a recently established risk strata endpoint, in contrast to prior models relying on WHO FC. For example, our study estimated a total of 5.05 LYs per patient, which is slightly lower than the range of estimates (5.72–7.31 LYs) from a Canadian health technology assessment for selexipag plus background therapy vs background therapy alone in PAH [18]. It was also lower than the range of estimates (7.11–9.19 LYs) in a published Australian study [25]. The lower LYs predicted in our analysis may be explained by not only difference in the modeled endpoint but also variations in the modeled population (shown in Supplementary Table 2). For example, our analysis was composed of previously treated patients with more advanced disease, resulting in a higher mortality risk compared with patients with newly diagnosed PAH in the Australian study. In addition, our study used more recent PAH mortality data from COMPERA, which is expected to result in our model producing more robust estimates.
In addition, given that our model relied heavily on STELLAR data (e.g., risk strata transition probabilities from weeks 0–3, weeks 3–12, and weeks 12–24), to ensure the robustness of our model results, we further performed an exploratory analysis using the risk strata transition probabilities over weeks 0–24 (i.e., the double-blind, placebo-controlled period) of STELLAR (Supplementary Table 4) and a model cycle length of 6 months. This exploratory analysis led to a gain of 10.7 years of life per patient, which closely aligned with the base case results of 11.5 years. This analysis further showed the stability of our model results when changing the way of incorporating STELLAR data.
To ensure the clinical plausibility of our model, the selection of parametric regression models used to inform our mortality inputs was based on goodness of fit in addition to clinical experts’ opinions. Parametric regression models with monotonically increasing hazards were considered clinically plausible to inform this population health model. Further external validation was conducted by comparing our estimated LYs for the background therapy alone arm with those reported in previously published population health models and registries.
Conclusion
In conclusion, in this population health model, adding sotatercept to background therapy demonstrated an increased life expectancy and reduction in utilization of infused prostacyclin, PAH hospitalizations, and lung/heart-lung transplants. These findings need to be confirmed by longer-term real-world studies.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T. Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States. Curr Med Res Opin. 2011;27(9):1763–8. https://doi.org/10.1185/03007995.2011.604310.
Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA. 2022;327(14):1379–91.
Burgoyne DS. Reducing economic burden and improving quality of life in pulmonary arterial hypertension. Am J Manag Care. 2021;27(3 Suppl):S53-s58. https://doi.org/10.37765/ajmc.2021.88611.
Badlam JB, Badesch DB, Austin ED, et al. United States Pulmonary Hypertension Scientific Registry: baseline characteristics. Chest. 2021;159(1):311–27. https://doi.org/10.1016/j.chest.2020.07.088.
Rahaghi FF, Balasubramanian VP, Bourge RC, et al. Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat. Pulm Circ. 2022;12(2):e12055. https://doi.org/10.1002/pul2.12055.
Chang KY, Duval S, Badesch DB, et al. Mortality in pulmonary arterial hypertension in the modern era: early insights from the Pulmonary Hypertension Association Registry. J Am Heart Assoc. 2022;11(9):e024969. https://doi.org/10.1161/jaha.121.024969.
Farber HW, Miller DP, Poms AD, et al. Five-Year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015;148(4):1043–54. https://doi.org/10.1378/chest.15-0300.
Hoeper MM, Pausch C, Grünig E, et al. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. Eur Respir J. 2022. https://doi.org/10.1183/13993003.02024-2021.
Spiekerkoetter E, Kawut SM, de Jesus Perez VA. New and Emerging Therapies for Pulmonary Arterial Hypertension. Annu Rev Med. 2019;70:45–59. https://doi.org/10.1146/annurev-med-041717-085955.
Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Eur Respir J. 2023. https://doi.org/10.1183/13993003.01347-2022.
Joshi SR, Liu J, Bloom T, et al. Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension. Sci Rep. 2022;12(1):7803. https://doi.org/10.1038/s41598-022-11435-x.
Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023;388:1478.
Iskandar R. A theoretical foundation for state-transition cohort models in health decision analysis. PLoS One. 2018;13(12):e0205543. https://doi.org/10.1371/journal.pone.0205543.
Institute for Clinical and Economic Review. ICER’s Reference Case for Economic Evaluations: Principles and Rationale. 2020.
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–731. https://doi.org/10.1093/eurheartj/ehac237.
Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119. https://doi.org/10.1093/eurheartj/ehv317.
Rosenkranz S, Pausch C, Coghlan JG, et al. Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis. J Heart Lung Transplant. 2023;42(1):102–14. https://doi.org/10.1016/j.healun.2022.10.003.
Canadian Agency for Drugs and Technologies in Health (CADTH). Reimbursement Reviews - Selexipag. Accessed June 1, 2022. https://www.cadth.ca/selexipag
Coyle K, Coyle D, Blouin J, et al. Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study. Pharmacoeconomics. 2016;34(5):509–20. https://doi.org/10.1007/s40273-015-0366-8.
Bernstein EJ, Bathon JM, Lederer DJ. Survival of adults with systemic autoimmune rheumatic diseases and pulmonary arterial hypertension after lung transplantation. Rheumatology (Oxford). 2018;57(5):831–4. https://doi.org/10.1093/rheumatology/kex527.
Sitbon O, Gomberg-Maitland M, Granton J, et al. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J. 2019. https://doi.org/10.1183/13993003.01908-2018.
McLaughlin VV, Hoeper MM, Channick RN, et al. Pulmonary arterial hypertension-related morbidity is prognostic for mortality. J Am Coll Cardiol. 2018;71(7):752–63.
Campo A, Mathai S, Le Pavec J, et al. Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur Respir J. 2011;38(2):359–67.
Burger CD, Long PK, Shah MR, et al. Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry. Chest. 2014;146(5):1263–73.
Tran-Duy A, Morrisroe K, Clarke P, et al. Cost-Effectiveness of Combination Therapy for Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension. J Am Heart Assoc. 2021;10(7):e015816. https://doi.org/10.1161/jaha.119.015816.
Besinque GM, Lickert CA, Pruett JA. The myth of the stable pulmonary arterial hypertension patient. Am J Manag Care. 2019;25(3 Suppl):S47-s52.
Taichman DB, McGoon MD, Harhay MO, et al. Wide variation in clinicians’ assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. Mayo Clin Proc. 2009;84(7):586–92. https://doi.org/10.1016/s0025-6196(11)60747-7.
Howard LS. Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease. Eur Respir Rev. 2011;20(122):236–42. https://doi.org/10.1183/09059180.00006711.
Highland KB, Crawford R, Classi P, et al. Development of the Pulmonary Hypertension Functional Classification Self-Report: a patient version adapted from the World Health Organization Functional Classification measure. Health Qual Life Outcomes. 2021;19(1):202. https://doi.org/10.1186/s12955-021-01782-0.
Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017. https://doi.org/10.1183/13993003.00889-2017.
Boucly A, Weatherald J, Savale L, et al. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. Eur Respir J. 2022. https://doi.org/10.1183/13993003.02419-2021.
Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019. https://doi.org/10.1183/13993003.01889-2018.
Hoeper MM, Pausch C, Olsson KM, et al. COMPERA 20: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022. https://doi.org/10.1183/13993003.02311-2021.
Pizzicato LN, Nadipelli VR, Governor S, et al. Real-world treatment patterns, healthcare resource utilization, and cost among adults with pulmonary arterial hypertension in the United States. Pulm Circ. 2022;12(2):e12090. https://doi.org/10.1002/pul2.12090.
Acknowledgements
The authors thank the patients, along with their families and caregivers, who participated in the STELLAR trial and the COMPERA registry, from which most of the clinical inputs of this study were obtained.
Prior Presentation
The data were presented at the annual congress of the European Respiratory Society in Milan, Italy, in September 2023.
Editorial Assistance
The authors thank Daan Mathijssen, an employee of OPEN Health, The Netherlands, for quality-checking the population health model and Christina DuVernay, an employee of OPEN Health, USA, for editorial assistance with the manuscript.
Funding
The design and conduct of this study, including the journal’s Rapid Service Fee and Open Access fee, were funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Author information
Authors and Affiliations
Contributions
All named authors meet International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have granted their approval for this version to be published.
Corresponding author
Ethics declarations
Conflict of Interest
Rongzhe Liu, Iman Nourhussein, and David Bernotas are employees (or were employees during conduct of this study) of OPEN Health, which received funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA to conduct the study. Adnan Alsumali, Janethe de Oliveira Pena, Rogier Klok, Dominik Lautsch, Jestinah Chevure and Eliana Martinez are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and hold stock in Merck & Co., Inc., Rahway, NJ, USA. Vallerie McLaughlin is a consultant for Aerovate, Altavant Sciences, Bayer, CVS Caremark, CorVista Health, Gossamer Bio, Janssen, Merck, and United Therapeutics; and has received grants from Aerovate, Altavant Sciences, Merck, Gossamer Bio, Janssen, and SoniVie; and received stocks from Clene. Christine Pausch has nothing to disclose. Marius M. Hoeper is a consultant and speaker for Acceleron Pharma, Inc, Actelion, AOP Orphan Pharmaceuticals, Bayer, Ferrer, GlaxoSmithKline, Janssen, and MSD.
Ethical Approval
This study relied on previously conducted studies and did not involve any new studies requiring the direct participation of human subjects; thus, ethics board approval was not required.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
McLaughlin, V., Alsumali, A., Liu, R. et al. Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH). Adv Ther 41, 130–151 (2024). https://doi.org/10.1007/s12325-023-02684-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-023-02684-x